コンテンツへスキップ
Merck

P0108

Sigma-Aldrich

PRL-3 Inhibitor I

≥98% (HPLC), solid

別名:

5-[[5-bromo-2-[(2-bromophenyl)methoxy]phenyl]methylene]-2-thioxo-4-thiazolidinone, Phosphatase of regenerating liver-3, Inhibitor I

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
C17H11Br2NO2S2
CAS番号:
分子量:
485.21
MDL番号:
UNSPSCコード:
12352200
PubChem Substance ID:
NACRES:
NA.77

品質水準

アッセイ

≥98% (HPLC)

フォーム

solid

保管条件

protect from light

yellow

溶解性

DMSO: >10 mg/mL
H2O: <2 mg/mL

保管温度

−20°C

SMILES記法

Brc1ccc(OCc2ccccc2Br)c(c1)\C=C3\SC(=S)NC3=O

InChI

1S/C17H11Br2NO2S2/c18-12-5-6-14(22-9-10-3-1-2-4-13(10)19)11(7-12)8-15-16(21)20-17(23)24-15/h1-8H,9H2,(H,20,21,23)/b15-8+

InChI Key

HXNBAOLVPAWYLT-OVCLIPMQSA-N

アプリケーション

PRL-3 Inhibitor I has been used as an inhibitor of phosphatase of regenerating liver-3 (PRL-3):
  • to test its effect on classical Hodgkin lymphoma cell survival
  • in the human umbilical vein endothelial cells tube formation assay
  • to test its effect on the migration of neural crest cells

生物化学的/生理学的作用

PRL-3 Inhibitor I is a rhodanine derivative with an IC50 value of 0.9 μM against phosphatase of regenerating liver-3 (PRL-3), a nonclassical protein tyrosine phosphatase that has recently been shown to be involved in cancer metastasis. PRL-3 Inhibitor I reduced the invasiveness of B16F10 melanoma cells in a cell based assay.

特徴および利点

This compound is featured on the Phosphoprotein Phosphatases (Tyrosine) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

保管分類コード

11 - Combustible Solids

WGK

WGK 3

個人用保護具 (PPE)

dust mask type N95 (US), Eyeshields, Gloves


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

P0108-VAR:
P0108-5MG:
P0108-BULK:


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

適切なバージョンが見つかりませんか。

特定のバージョンが必要な場合は、ロット番号またはバッチ番号で特定の証明書を検索できます。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

E G Garcia et al.
Leukemia, 35(3), 679-690 (2020-07-02)
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of thymocytes and is largely driven by the NOTCH/MYC pathway. Yet, additional oncogenic drivers are required for transformation. Here, we identify protein tyrosine phosphatase type 4 A3 (PRL3) as a collaborating
Ying-Qian Lu et al.
Stem cell research, 34, 101354-101354 (2019-01-06)
The human iPS cell line, hiPS-SPG76 (FJMUi001-A), derived from skin fibroblasts from a 42-year-old male hereditary spastic paraplegia patient carrying compound heterozygous p.P498L (c.1493C > T) and p.R618W (c.1852C > T) mutations in the CAPN1 gene, was generated by non-integrative reprogramming vectors encoding OCT3/4
Jin Hee Ahn et al.
Bioorganic & medicinal chemistry letters, 16(11), 2996-2999 (2006-03-15)
A series of rhodanine derivatives was synthesized and evaluated for their ability to inhibit PRL-3. Benzylidene rhodanine derivative showed good biological activity, while compound 5e was the most active in this series exhibiting an IC50 value of 0.9 microM in
Jianliang Xu et al.
PloS one, 6(11), e27165-e27165 (2011-11-11)
Phosphatase of regenerating liver 3 (PRL-3) is known to be overexpressed in many tumors, and its transcript level is high in the vasculature and endothelial cells of malignant tumor tissue. However, the mechanism(s) underlying its enhanced expression and its function
Magnus Aassved Hjort et al.
Experimental hematology & oncology, 7, 8-8 (2018-04-14)
Phosphatase of regenerating liver-3 (PRL-3) is implicated in oncogenesis of hematological and solid cancers. PRL-3 expression increases metastatic potential, invasiveness and is associated with poor prognosis. With this study, we aimed to show a possible oncogenic role of PRL-3 in

資料

Protein tyrosine phosphatases' catalytic mechanism involves transient phosphorylation.

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)